



PROSONIX SUCCESSFULLY SCALES UP UMAX[®] TECHNOLOGY FOR RESPIRATORY MEDICINES

NEW FOCUS ON ENABLING PRODUCT DEVELOPMENT

30th March 2010

Prosonix (Oxford, UK) is delighted to announce the successful scale up of UMAX[®], its new particle engineering technology that is set to revolutionise respiratory medicine. The scale-up has now been demonstrated on multiple APIs in cGMP facilities. Importantly Prosonix and its partners have shown a seamless transition from laboratory to commercial scale batches, with no loss of formulation performance, independent of delivery platform or device.

The proprietary UMAX[®] technology delivers unique, crystalline, excipient free, highly performing, stable drug particles, that offer significant and distinct and quantifiable advantages over current industry practice, and now enables the development and optimisation of a wide range of mono and combination inhalation therapies. Successfully demonstrated on over 30 generic and novel drug molecules and combinations, customer demand is driving the rapid commercialisation program.

Critically the new UMAX[®] approach does not utilise destructive high energy milling classically used in the preparation of inhalation medicines. This historic methodology introduces significant variability into drug product and formulation performance with respect to delivered dose, dose content uniformity, dose-to-dose variation, and restricts product shelf life. In addition UMAX[®] does not require the use of any Force Control Agents or exotic excipients in the formation of its' unique crystalline constructs, offering significant benefits in ease of formulation and device reliability, and removing potential safety concerns over long term exposure to chemical additives.

Commenting on the latest developments, David Hipkiss Prosonix CEO said

“Prosonix is focused on “Making Better Medicines[™]”. This latest success further de-risks our novel particle engineering approach and proves beyond doubt that UMAX[®] is here to stay. It should now be considered as the technology of choice for the future development of respiratory medicines.

Our portfolio of engineered pharmaceutical mono and combination inhalation therapy products, offer distinct and high value advantages to patients, healthcare providers and payors alike. Formulation testing is well advanced and we look forward to making additional success based announcements in the months ahead”

For more information contact:

David Hipkiss
CEO
Prosonix Ltd
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA, UK

Tel + 44 (0) 1865 784 250
Web www.prosonix.co.uk



Notes for Editors Correct as of 30 March 2010

About Prosonix Ltd

www.prosonix.co.uk

Based in Oxford UK, Prosonix's team of chemists and engineers combine to give Prosonix a unique multidisciplinary approach and competitive advantage to solve customers complex particle engineering and product problems, leveraging its proprietary intellectual property and patented ultrasonic processing equipment to deliver long term and sustainable value added solutions, enabling the cost effective manufacture of better medicines.

Prosonitron[®], Prosonix's world leading patented sonocrystallization process and reactor technology is already proven across scale, facilitating the Complete Crystallization Control[™] of many aspects of complex pharmaceutical crystallization processes, including control of crystal size, shape, purity, the selective production of polymorphs, enhancing both manufacturing productivity and ultimate formulation performance. New and proprietary process variants include DISCUS[™]-I and DISCUS[™]-M for the advanced particle engineering of microcrystalline active ingredients. In addition a new range of small scale SonoLab[™] equipment is now available for laboratory and kilo lab use. Prosonitron technology is increasingly being recognised as the *defacto* first choice in pharmaceutical API crystallization and isolation. In this regard, Prosonix announced in September 2008 that Pfizer Group Manufacturing had selected the Prosonitron technology for implementation at its primary manufacturing Ringaskiddy facilities in Ireland.

UMAX[®] and SAX[™] are proprietary *Solution-to-Particle* sonocrystallization processes technologies with world beating potential for inhalation drug delivery. These build on Prosonix core Prosonitron[™] technology. Both processes can produce highly engineered single and combination microcrystalline drug particles that are ideally suited for inhalation, without the need for destructive milling or micronisation processes. Prosonix have proven *in-vitro* that the resultant particles have better stability, formulation consistency, eliminates dose-to-dose variation and could exhibit potentially improved efficacy per unit dose than those made by other techniques. UMAX[®] is a new and proprietary process technology discovered and developed exclusively by Prosonix. Prosonix in-licensed the SAX[™] technology from the University of Bath on a world wide exclusive basis in February 2007. .

In January 2008 Prosonix in-licensed a novel particle rounding technology process patent (PRT) from Rafael Industries(Haifa, Israel) Importantly the process patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include the post crystallization particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging. Used in combination, the PRT and the proven Prosonix Prosonitron process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems.

Underpinning Prosonix's leadership in commercializable crystallization technology is CrystalGEM[™] and SonoLab[™]. Marketed in partnership with Chiralabs (Oxford, UK) the CrystalGEM[™] offering is a unique and award winning predictive crystallization service that significantly enhances crystallization screening productivity in pharmaceutical development. SonoLab[™] is a suite of designed for purpose small scale reactors that can be used by the laboratory chemist with confidence, knowing that a proven scale up method already exists. In October 2008, Prosonix announced a worldwide sole marketing partnership with Syrris (Royston, UK) positioning Syrris as the prime channel to market for the new SonoLab[™] range.

Complementing its market led internal R&D programs, Prosonix is engaged with several strategic partnerships with leading academic and technology institutions, including the University of Bath, University of Coventry, and the University of Leeds.

Prosonix is further supported by leading industrial and academic consultants including but not limited to Professor Rob Price (University of Bath, UK), Professor Kevin Roberts (University of Leeds, UK) and Professor Tim Mason (University of Coventry), and Dr Steve Nichols former Head of Inhalation at Sanofi-Aventis UK.

----- ENDS -----